Advanced Prostate Cancer

Advanced Prostate Cancer/

The PREVAIL Trial Shows That Enzalutamide Not Only Increases Overall Survival Over Placebo, It Also Delays the Onset Of The First Skeletal Event

Analysis of the PREVAIL Trial showed that Enzalutamide (Xtandi) significantly increased overall survival and radiographic progression-free survival compared with placebo in men with prostate cancer who were asymptomatic and minimally symptomatic, chemotherapy-naive and who had metastatic castration-resistant prostate cancer (mCRPC).

Now, an additional analysis of the data has shown the effect enzalutamide also has on health-related quality of life (HRQoL). These criteria include pain and skeletal-related events experienced during the trial.

The researchers utilized the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and EQ-5D questionnaires to measure the participant’s reported HRQoL. Measurements were taken at baseline and during treatment. Pain status was also […]

SEER PSA Data Is Flawed and Removed By the NCI – What Are the Implications for the Flawed USPTF PSA Debacle?

I am not sure what to do with this information, but it certainly could be described as a rather large elephant in the room. We all are very familiar with the prostate cancer PSA test controversy brought on by the United States Preventive Task Force (USPTF). To quickly review the issue, the USPTF developed a recommendation that the PSA test resulted in more harm than good when it was used for the screening of men for prostate cancer. Now we have just had a huge monkey wrench thrown into the equation!

The National Cancer Institute (NCI) recently announced that it had […]

By |May 20th, 2015|General Information, PSA, Research, Screening, Uncategorized, USPTF|0 Comments

The Development of A Novel Blood Biomarker for Detecting AR-V7 and Resistance to Zytiga and Xtandi

At the current AUA Annual Meeting going on in New Orleans, there was a presentation given by Haitao Zhang and colleagues. They described their work developing a novel blood-based assay (test) for detecting androgen receptor (AR) splice variants in men with advanced prostate cancer.

Their work relies on the premise that AR-V7 expression underlies resistance to abiraterone (Zytiga) and enzalutamide (Xtandi) (This issue is discussed in many other posts on this blog, additional information s available by searching AR-V7). Their work involved the development of a new blood-based assay to detect AR-V expression without the need for CTC isolation, which s […]

Predicting the Long-Term Survival of Men with A Biochemical Recurrence Post-Surgery Who Are Hormone Naive Can Change How We Treat Them

Appearing in the European Journal of Nuclear Medicine and Molecular Imaging a recent study provides data on the long-term survival of men with a biochemical recurrence after failed surgery.

In the study by Giovacchini et al. it was shown that a PET/CT scan (specifically a choline PET/CT) could predict the long-term survival of men who are hormone-naive (not yet started ADT) who had a biochemical failure (where biochemical failure was defined by a PSA level > 0.2 ng/ml post surgery).

The study was a retrospective analysis of  302 men who were hormone-naive and who had been previously treated with a radical prostatectomy. […]